van Eijkeren 1992.

Methods	Randomisation list controlled by pharmacy Double‐blind, placebo‐controlled, parallel group No ITT and no power calculation made 7 withdrawals (postponed hysterectomy, fibroids at operation, postmenstrual phase, premenstrual phase). 1 discontinuation because of adverse effects of MFA (rash and itching)
Participants	Netherlands 19 women, mean age 40 years Inclusion criteria: aged < 45 years, MBL > 80 mL/cycle, regular menstrual cycle Exclusion criteria: IUD, use of NSAIDs or other medication that could affect haemostasis, contraindications against NSAIDs, use of hormonal medication
Interventions	Group 1: MFA 500 mg 3 times daily from 5 days prior to menses to cessation of bleeding, n = 6 Group 2: placebo 3 times daily from 5 days prior to menses to cessation of bleeding, n = 5 Duration: 1 menstrual cycle
Outcomes	MBL (alkaline haematin method) Adverse events
Notes	19 women randomised but 7 dropped out after the treatment cycle (this high dropout rate reduced the quality of the study). Data reported only for the 11 women that went on to have a hysterectomy. Requested data from the 7 withdrawals but received no answer from author.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomisation list controlled by pharmacy
Allocation concealment (selection bias)	Low risk	Outside control of randomisation list
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blind
Incomplete outcome data (attrition bias) All outcomes	High risk	7/19 women withdrawn (postponed hysterectomy, fibroids at operation, postmenstrual phase, premenstrual phase, adverse effects of MFA) and 1 woman discontinuation because of adverse effects; no ITT analysis
Other bias	Unclear risk	Nothing detected